Phase I-II evaluation of intra-arterial @entity29601 for recurrent malignant XXXX .

@entity1 @entity137 @entity1313 @entity5 @entity29601 @entity3600 @entity816
@entity29601 ( @entity29601 ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in @entity5 models. Five of 12 @entity1 with @entity5 treated with iv AZQ had clinical and/or radiographic improvement (Schold, Neurology 34:615, 1984). Intra-arterial administration of AZQ to @entity1 with @entity1313 should produce higher peak levels of drug in the @entity5 and should reduce systemic @entity137 . Twenty-one @entity1 with @entity816 (grade II, four; grade III, 11; and grade IV, six), in all of whom irradiation and intra-arterial @entity3600 chemotherapy failed, received intra-arterial AZQ as a single dose every 28 days. Two of 20 evaluable @entity1 experienced partial responses of 5 and 8+ months, respectively. Four @entity1 had disease stabilization of 3, 4, 5, and 8 months' duration, respectively, and one of these @entity1 had @entity5 shrinkage (partial response) after seven courses of AZQ. The initial dose in the first three @entity1 was 10 mg/m2, and doses in subsequent groups of three @entity1 were begun at increases of 5 mg/m2. The within-group dose escalation was 5 mg/m2 per course if there was no hematologic @entity137 . Dose-limiting @entity137 was myelosuppression, which occurred at doses greater than 15 mg/m2. The maximum tolerated dose was 25 mg/m2. Intra-arterial AZQ appears to be of marginal effectiveness in @entity1 refractory to carmustine and offers no advantage over iv AZQ in efficacy or @entity137 .
